share_log

FibroGen (NASDAQ:FGEN) Shares Gap Up to $12.44

FibroGen (NASDAQ:FGEN) Shares Gap Up to $12.44

FibroGen(納斯達克：FGEN)股價差距高達12.44美元
Financial News Live ·  2022/09/28 23:01

Shares of FibroGen, Inc. (NASDAQ:FGEN – Get Rating) gapped up prior to trading on Wednesday . The stock had previously closed at $12.44, but opened at $13.05. FibroGen shares last traded at $12.86, with a volume of 971 shares trading hands.

週三，FibroGen，Inc.(納斯達克代碼：FGEN-GET評級)的股價在交易前大幅上漲。該股此前收盤報12.44美元，開盤報13.05美元。FibroGen的股票最新報12.86美元，成交量為971股。

Analysts Set New Price Targets

分析師設定新的價格目標

Several equities research analysts recently commented on the stock. StockNews.com cut shares of FibroGen from a "buy" rating to a "hold" rating in a research report on Wednesday, August 10th. Cowen upped their target price on shares of FibroGen to $14.00 in a report on Monday, August 15th.

幾位股票研究分析師最近對該股發表了評論。在8月10日星期三發佈的一份研究報告中，StockNews.com將FibroGen的股票評級從“買入”下調至“持有”。考恩在8月15日星期一的一份報告中將FibroGen的股票目標價上調至14.00美元。

Get
到達
FibroGen
光纖發電
alerts:
警報：

FibroGen Stock Performance

FibroGen股票表現

The firm has a market cap of $1.21 billion, a P/E ratio of -5.25 and a beta of 0.88. The company's 50 day moving average is $13.03 and its 200 day moving average is $11.65.

該公司的市值為12.1億美元，市盈率為-5.25，貝塔係數為0.88。該公司的50日移動均線切入位在13.03美元，200日移動均線切入位在11.65美元。

FibroGen (NASDAQ:FGEN – Get Rating) last issued its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.78) EPS for the quarter, beating the consensus estimate of ($0.94) by $0.16. The business had revenue of $29.81 million during the quarter, compared to the consensus estimate of $36.15 million. FibroGen had a negative net margin of 83.64% and a negative return on equity of 100.51%. The firm's revenue was up 22.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($1.45) EPS. On average, equities research analysts anticipate that FibroGen, Inc. will post -3 EPS for the current year.
FibroGen(納斯達克：FDEN-GET評級)上一次發佈季度收益數據是在8月8日星期一。這家生物製藥公司公佈了本季度每股收益(0.78美元)，比普遍預期的(0.94美元)高出0.16美元。該業務本季度的收入為2981萬美元，而普遍預期為3615萬美元。FibroGen的淨利潤率為負83.64%，淨資產回報率為負100.51%。與去年同期相比，該公司的收入增長了22.3%。去年同一季度，該公司每股收益為1.45美元。平均而言，股票研究分析師預計FibroGen，Inc.將公佈本年度每股收益為3美元。

Hedge Funds Weigh In On FibroGen

對衝基金對FibroGen的看法

Several large investors have recently modified their holdings of the business. Sigma Planning Corp raised its stake in shares of FibroGen by 4.6% during the second quarter. Sigma Planning Corp now owns 23,775 shares of the biopharmaceutical company's stock valued at $251,000 after acquiring an additional 1,050 shares during the last quarter. Guggenheim Capital LLC raised its stake in shares of FibroGen by 5.4% during the first quarter. Guggenheim Capital LLC now owns 23,540 shares of the biopharmaceutical company's stock valued at $283,000 after acquiring an additional 1,203 shares during the last quarter. Arizona State Retirement System raised its stake in shares of FibroGen by 5.8% during the second quarter. Arizona State Retirement System now owns 23,868 shares of the biopharmaceutical company's stock valued at $252,000 after acquiring an additional 1,313 shares during the last quarter. Kestra Advisory Services LLC increased its position in shares of FibroGen by 12.6% during the first quarter. Kestra Advisory Services LLC now owns 13,448 shares of the biopharmaceutical company's stock worth $162,000 after buying an additional 1,500 shares during the period. Finally, Nisa Investment Advisors LLC increased its position in shares of FibroGen by 369.7% during the second quarter. Nisa Investment Advisors LLC now owns 2,795 shares of the biopharmaceutical company's stock worth $30,000 after buying an additional 2,200 shares during the period. Institutional investors own 74.76% of the company's stock.

幾家大型投資者最近調整了對該公司的持股。西格瑪規劃公司在第二季度將其在FibroGen的股份增加了4.6%。西格瑪規劃公司目前擁有23,775股這家生物製藥公司的股票，價值251,000美元，此前該公司在上個季度又收購了1,050股。古根海姆資本有限責任公司在第一季度將其在FibroGen的股份增加了5.4%。古根海姆資本有限責任公司現在擁有23,540股這家生物製藥公司的股票，價值28.3,000美元，在上個季度又購買了1,203股。亞利桑那州退休系統在第二季度將其在FibroGen的股份增加了5.8%。亞利桑那州退休系統現在擁有23,868股這家生物製藥公司的股票，價值252,000美元，在上個季度額外購買了1,313股。Kestra Consulting Services LLC在第一季度將其在FibroGen的股票頭寸增加了12.6%。Kestra Consulting Services LLC現在擁有這家生物製藥公司13,448股股票，價值162,000美元，在此期間又購買了1,500股。最後，NISA Investment Advisors LLC在第二季度將其在FibroGen的股票頭寸增加了369.7%。NISA Investment Advisors LLC現在持有這家生物製藥公司2,795股股票，價值3萬美元，在此期間又購買了2,200股。機構投資者持有該公司74.76%的股份。

FibroGen Company Profile

FibroGen公司簡介

(Get Rating)

(獲取評級)

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.

FibroGen，Inc.是一家生物製藥公司，發現、開發和商業化治療嚴重未得到滿足的醫療需求的療法。該公司正在開發一種口服低氧誘導因子Pro羥基酶小分子抑制劑roxadustat，該藥已在美國、歐洲、中國和日本完成了治療慢性腎臟疾病貧血的第三階段臨牀開發，並在中國完成了治療與骨髓增生異常綜合徵相關的貧血的第二/第三階段臨牀開發。

Recommended Stories

推薦故事

  • Get a free copy of the StockNews.com research report on FibroGen (FGEN)
  • Mullen Automotive Is Ready To Get In Gear
  • Cracker Barrel: A Tasty Treat Or Bad Apple?
  • Defensive Stocks For A Volatile Market
  • SunPower Is Ready To Power Up Triple-Digit Earnings Gains
  • Will UPS Be Next to Deliver a Warning?
  • 免費獲取StockNews.com關於FibroGen的研究報告(Fgen)
  • 馬倫汽車已做好準備投入使用
  • 餅乾桶：可口的款待還是壞蘋果？
  • 防禦性股票應對動盪的市場
  • SunPower準備推動三位數的收益增長
  • UPS會成為下一個發出警告的公司嗎？

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.

接受FibroGen Daily的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對FibroGen和相關公司的最新新聞和分析師評級的每日簡要摘要。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論